Pulmonx Corporation will release Q3 2025 financial results on October 29, followed by a management conference call.
Quiver AI Summary
Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, announced it will release its financial results for the third quarter of 2025 on October 29, 2025, after market close. Following the announcement, company management will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties can register online to receive dial-in details for the call, which will also be available as a live and archived webcast on the Pulmonx website. Pulmonx is known for its Zephyr® Endobronchial Valve, among other products, which are widely used in the treatment of severe emphysema and are recognized as standard care options globally.
Potential Positives
- Announcement of financial results and scheduled conference call indicates transparency and engagement with investors.
- Company's focus on minimally invasive treatments positions it as a leader in the medical field, particularly for chronic obstructive pulmonary disease (COPD).
- FDA pre-market approval of the Zephyr Valve as a "breakthrough device" highlights innovation and credibility in Pulmonx’s product offerings.
- Wide availability of the Zephyr Valve in over 25 countries and inclusion in global treatment guidelines enhances market reach and reinforces its standard of care status.
Potential Negatives
- None
FAQ
When will Pulmonx release their Q3 2025 financial results?
Pulmonx will release their Q3 2025 financial results on October 29, 2025, after the market closes.
What time is the Pulmonx conference call?
The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET.
How can I participate in the Pulmonx conference call?
Interested parties can register for the call using an online form provided in the press release.
Where can I find the webcast of the conference call?
The live and archived webcast will be available in the “Investors” section of the Pulmonx website.
What treatments does Pulmonx offer for lung disease?
Pulmonx specializes in minimally invasive treatments for COPD, including the Zephyr® Endobronchial Valve.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LUNG Insider Trading Activity
$LUNG insiders have traded $LUNG stock on the open market 28 times in the past 6 months. Of those trades, 1 have been purchases and 27 have been sales.
Here’s a breakdown of recent trading of $LUNG stock by insiders over the last 6 months:
- DANIEL P FLORIN purchased 23,321 shares for an estimated $71,362
- DAVID AARON LEHMAN (GENERAL COUNSEL) has made 0 purchases and 9 sales selling 20,226 shares for an estimated $48,366.
- STEVEN S. WILLIAMSON (PRESIDENT AND CEO) has made 0 purchases and 4 sales selling 19,571 shares for an estimated $46,495.
- MEHUL JOSHI (Chief Financial Officer & PAO) has made 0 purchases and 4 sales selling 15,997 shares for an estimated $37,928.
- GEOFFREY BERAN ROSE (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 9 sales selling 13,490 shares for an estimated $32,216.
- RICHARD FERRARI sold 8,000 shares for an estimated $25,280
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LUNG Hedge Fund Activity
We have seen 57 institutional investors add shares of $LUNG stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,575,901 shares (-45.5%) from their portfolio in Q2 2025, for an estimated $4,081,583
- FMR LLC removed 1,156,888 shares (-21.4%) from their portfolio in Q2 2025, for an estimated $2,996,339
- MILLENNIUM MANAGEMENT LLC added 958,048 shares (+459.5%) to their portfolio in Q2 2025, for an estimated $2,481,344
- GSA CAPITAL PARTNERS LLP added 423,725 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,097,447
- BANK OF AMERICA CORP /DE/ added 407,971 shares (+556.6%) to their portfolio in Q2 2025, for an estimated $1,056,644
- FRANKLIN RESOURCES INC removed 357,936 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $927,054
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 303,246 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $785,407
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LUNG Analyst Ratings
Wall Street analysts have issued reports on $LUNG in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 09/08/2025
- Stifel issued a "Buy" rating on 07/31/2025
- Lake Street issued a "Buy" rating on 07/31/2025
- Canaccord Genuity issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for $LUNG, check out Quiver Quantitative's $LUNG forecast page.
$LUNG Price Targets
Multiple analysts have issued price targets for $LUNG recently. We have seen 7 analysts offer price targets for $LUNG in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $16.0 on 09/08/2025
- Larry Biegelsen from Wells Fargo set a target price of $3.0 on 08/01/2025
- Jason Bednar from Piper Sandler set a target price of $2.5 on 07/31/2025
- Frank Takkinen from Lake Street set a target price of $8.0 on 07/31/2025
- Rick Wise from Stifel set a target price of $5.0 on 07/31/2025
- Joanne Wuensch from Citigroup set a target price of $4.15 on 05/22/2025
- Jon Young from Canaccord Genuity set a target price of $15.0 on 05/01/2025
Full Release
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Parties interested in participating by phone should register using this online form . After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/ .
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr
®
Endobronchial Valve, Chartis
®
Pulmonary Assessment System, LungTraX™ Platform, and StratX
®
Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit
www.Pulmonx.com
.
Pulmonx ® , AeriSeal ® , Chartis ® , StratX ® , and Zephyr ® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
[email protected]
